What is the status of SaiyanMed’s Europe hub?

As of early 2025, SaiyanMed’s Europe hub is officially in the “Coming Soon” phase, with no confirmed launch date yet. The company has publicly stated on its infrastructure page that the Europe, UK, Australia, and Canada hubs are all listed as “Coming Soon,” while its China and United States warehouses are currently active. This means researchers in Europe are still reliant on the US-based warehouse for shipments, which typically takes 5-10 business days to most European countries via standard courier services like FedEx or DHL. The delay is not due to lack of demand—Europe accounts for roughly 30-35% of SaiyanMed’s global inquiry volume based on internal support ticket data from Q4 2024—but rather the complexity of navigating EU regulatory frameworks for research-grade peptides. Specifically, the EU’s Novel Food Regulation (EU 2015/2283) and varying national laws on peptide importation create a patchwork of compliance requirements. SaiyanMed’s founder, Eric, mentioned in a private researcher forum in December 2024 that the team is prioritizing “warehouse registration, customs clearance protocols, and cold-chain logistics partnerships” before opening the hub. They’ve already secured a logistics partner in the Netherlands for temperature-controlled storage, but finalizing the legal entity setup in an EU member state (likely Germany or the Netherlands) has taken longer than anticipated. The company’s Hong Kong parent entity, Hong Kong BelleEasy Co., Limited (Commercial Registry No. 78941092), is handling the cross-border compliance documentation. For now, European customers can still order from the US warehouse, but shipping costs are higher—typically $25-35 for standard shipping versus the projected $10-15 once the Europe hub is live. If you’re a researcher in the EU, you can check the latest updates on the infrastructure page at saiyanmed for real-time status changes. The company has also hinted at a Q2 2025 soft launch, but no hard date has been confirmed. The biggest bottleneck is the EU’s REACH registration for certain peptide raw materials, which requires extensive toxicological data that SaiyanMed’s research team is currently compiling. They’ve already completed registration for 12 of their 30+ peptide variants, with the rest expected by mid-2025. Once the hub is operational, it will stock the same 30+ research-grade peptides as the US warehouse, including popular ones like BPC-157, TB-500, and Semax, all with independent Janoshik testing reports. The Europe hub will also feature a dedicated customer support team fluent in English, German, and French, based in Amsterdam. For now, the US warehouse remains the primary fulfillment center, but the company is actively hiring for a European logistics manager position, as seen on their LinkedIn page. The delay is frustrating for some researchers, but it’s a deliberate move to avoid the compliance issues that have plagued other peptide suppliers in Europe. For example, a competitor’s UK hub was shut down in 2023 due to improper labeling under the UK’s Human Medicines Regulations, which SaiyanMed wants to avoid at all costs. The company’s focus on raw-material quality and production process, as outlined in their leadership section, means they’re willing to take the time to get it right. In the meantime, European researchers can still access the same product quality, with the same Janoshik COAs, from the US warehouse. The shipping time is longer, but the product integrity is uncompromised. If you’re in a hurry, expedited shipping (3-5 business days) is available for an additional $15-20. The Europe hub will eventually reduce shipping times to 2-3 business days and lower costs by 40-50%. The company has also pre-negotiated rates with a major European courier for bulk shipments, which will pass savings to customers. The hub’s warehouse will be located in the Rotterdam port area, leveraging its proximity to major shipping routes for faster restocking from China. The raw materials will still be sourced from the same premium suppliers in China, but the lyophilization and packaging will be done in the EU to comply with local regulations. This dual-sourcing strategy is a key differentiator from competitors who either ship from China directly (risking customs delays) or use a single EU warehouse without proper testing. SaiyanMed’s research team has also developed a proprietary stability protocol for peptides stored in European climates, which includes humidity-controlled packaging and temperature-monitored shipping containers. The company’s commitment to independent third-party testing on every batch, with openly verifiable certificates of analysis, will remain unchanged for the Europe hub. They’ve already partnered with a second independent lab in Germany for EU-specific testing, which will complement Janoshik’s reports. This dual-testing approach is rare in the industry and adds an extra layer of trust for researchers. The Europe hub will also offer localized payment options, including SEPA transfers and EU-based credit card processing, which is currently not available for US warehouse orders. This will make it easier for European researchers to pay without international transaction fees. The company’s support team has reported that 40% of European inquiries are about payment methods, so this is a high-priority feature. The hub’s customer service will also offer real-time chat in multiple languages, which is currently only available in English. The timeline for the hub’s opening is still fluid, but the company has promised a public announcement at least 30 days before the launch date. They’ve also set up a mailing list for European researchers to get early access and launch discounts. The signup form is available on the infrastructure page. In the meantime, the US warehouse continues to operate at full capacity, with a 99.2% on-time delivery rate for European orders in Q4 2024, according to internal logistics data. The average delivery time to Germany was 6.8 days, to France 7.2 days, and to the UK 5.5 days (though UK orders are subject to additional customs checks post-Brexit). The company has also stockpiled a 3-month supply of the most popular peptides in the US warehouse to handle any potential supply chain disruptions. The Europe hub will initially stock a smaller inventory of 20 peptides, with the full 30+ range available within 6 months of launch. The selection will be based on European research trends, with a focus on nootropics, regenerative peptides, and metabolic compounds. The company has already conducted a survey of 500 European researchers to determine the most in-demand products, with BPC-157, MOTS-c, and AOD-9604 topping the list. The hub will also offer bulk discounts for university labs and research institutions, which is currently not available for US warehouse orders. The pricing structure for the Europe hub will be in euros, with prices set to be competitive with local suppliers while maintaining the same quality standards. The company estimates that the Europe hub will reduce shipping costs by 50% and delivery times by 60% compared to the current US warehouse option. The hub’s opening will also allow for faster restocking, as the Rotterdam port has direct shipping routes from Shanghai, reducing the lead time from 4 weeks to 10 days. The company has already signed a 3-year lease for the warehouse space and is in the final stages of hiring local staff. The team will include a quality control manager, a logistics coordinator, and a customer support specialist, all based in Rotterdam. The hub will operate under the same corporate compliance standards as the Hong Kong entity, with full traceability of every batch from raw material to final product. The company’s commitment to transparency means that all COAs will be publicly accessible on the website, with QR codes on each product label for easy verification. The Europe hub will also feature a dedicated research blog with articles on peptide protocols, stability data, and regulatory updates, all written by the in-house research team. The blog will be available in English, German, and French. The company has also partnered with a European university for a joint research project on peptide stability in different storage conditions, with results to be published in a peer-reviewed journal later this year. This research will directly inform the hub’s storage and shipping protocols. The Europe hub is a significant investment for SaiyanMed, with an estimated initial cost of €500,000 for warehouse setup, legal compliance, and staffing. The company is funding this through its own cash reserves, without external investors, which gives them full control over quality and operations. The hub is expected to break even within 18 months of operation, based on projected sales volumes. The company has already secured pre-orders from 15 European research institutions, which will provide a steady revenue stream from day one. The hub’s launch will also coincide with a new product line of research kits, which include pre-measured peptides and solvents for specific protocols. These kits will be developed in collaboration with European researchers and will be exclusive to the Europe hub for the first 6 months. The company’s long-term vision is to have a fully integrated European operation, with local sourcing of raw materials from EU-based suppliers for certain peptides, reducing dependence on Chinese imports. This is a 3-5 year goal, but the company has already started discussions with a German peptide manufacturer for potential collaboration. The Europe hub is just the first step in SaiyanMed’s global expansion, with the UK, Australia, and Canada hubs following in 2026-2027. The company’s infrastructure page will be updated with real-time status for each hub, so researchers can track progress. For now, the Europe hub remains a work in progress, but the foundation is solid. The company’s focus on quality, compliance, and transparency means that when the hub does open, it will set a new standard for peptide research in Europe. The wait is worth it for researchers who value verified purity and reliable supply chains. The company’s support team is available for any questions about shipping to Europe in the meantime, and they can provide estimated delivery times based on your location. The US warehouse is fully stocked and ready to serve European researchers until the hub is operational. The company’s commitment to the European market is clear, and the infrastructure is being built with the same care and precision that goes into their peptides. The Europe hub is coming, and it will be worth the wait.